Cheap deep space exploration missions hold promise for Rocket Lab -- and peril for the dinosaurs of space.
Get ready for a summer of booming biotech stocks.
A proposal to nullify intellectual property regarding COVID-19 vaccines seems unlikely to affect Moderna's bottom line.
With a third of revenue coming from "Call of Duty" last year, is Activision too dependent on this best-selling title?
The game maker turned in a stellar quarter and is ramping up investment for long-term growth.
More people are playing the company's video games than ever before.
It's going to become the must-have device of the high-end smartphone market.
Dynetics and Blue Origin are upset over SpaceX's $2.9 billion moon contract win.
The smartphone giant's latest lineup is dominating global sales charts.
One analyst sees gains of nearly 40% ahead for the biotech's shareholders.